Trial Profile
A Phase 1, Randomized, Single-Blind, Placebo Controlled, Single-Ascending Dose, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Subcutaneously Administered ALN-TTRSC02 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Vutrisiran (Primary)
- Indications Transthyretin-related hereditary amyloidosis
- Focus Adverse reactions
- Sponsors Alnylam Pharmaceuticals
- 29 Jun 2020 Results published in the Clinical Pharmacology and Therapeutics
- 28 Mar 2018 Results presented in the Alnylam Pharmaceuticals media release.
- 28 Mar 2018 According to an Alnylam Pharmaceuticals media release data from this trial was presented at the 16th International Symposium on Amyloidosis (ISA) (2018).